NF-κB, inflammation, immunity and cancer: coming of age

Nat Rev Immunol. 2018 May;18(5):309-324. doi: 10.1038/nri.2017.142.

Koji Taniguchi ¹ ² ³, Michael Karin ³

Affiliations

1 Department of Microbiology and Immunology, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan.
2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
3 Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.

PMID: 29379212 DOI: 10.1038/nri.2017.142

Abstract

Fourteen years have passed since nuclear factor-κB (NF-κB) was first shown to serve as a molecular lynchpin that links persistent infections and chronic inflammation to increased Cancer risk. The young field of inflammation and Cancer has now come of age, and inflammation has been recognized by the broad Cancer research community as a hallmark and cause of Cancer. Here, we discuss how the initial discovery of a role for NF-κB in linking inflammation and Cancer led to an improved understanding of tumour-elicited inflammation and its effects on Anticancer immunity.

Name
Email *

	Sorry, but the email address you supplied was invalid.